护肝清脂片对非酒精性脂肪肝大鼠的药效学研究

Pharmacodynamics research of Huganqingzhi Tablet on rats with non-alcoholic fatty liver model

目的:研究护肝清脂片对非酒精性脂肪肝的药效情况。方法:大鼠按体重随机分为空白组、模型组、非诺贝特组(0.1g/kg)、护肝清脂片高(2.16g/kg)、中(1.08g/kg)、低剂量组(0.54g/kg)。采用高脂饲料造模,同时给予各组大鼠相应的药物连续10周。实验结束后,腹主动脉采血并处死所有大鼠,观察大鼠肝组织病理改变情况,并测定各组大鼠的血脂、肝指数、血糖、肝脏抗氧化能力等指标。结果:相较于模型组,护肝清脂片高、中剂量组大鼠的肝指数和MDA都明显下降;SOD、CAT、TAOC则明显升高。结论:护肝清脂片高(2.16g/kg)、中(1.08g/kg)剂量组能有效改善及预防非酒精性脂肪肝模型大鼠脂肪变性及炎症损伤,具有降低血脂水平、提高抗氧化能力等疗效。

To researeb and evaluate the efficacy of Huganqingzhi tablet in treatment of non-alcoholic fatty liver disease （NAFLD）. Methods： According to the body weight, sixty male rats were randomly divided into six groups： blank control group, model group, Fenofi-brate tablet group （0. lg/kg）, Huganqingzhi tablet high（2. 16g/kg） ,middle （1.08g/kg） and low dose （0.54g/kg） groups. Rats of all groups except the blank control group were fed a high-fat diet and all the rats were given by the relevant treatments for ten weeks to induce NAFLD. Hepatic histopathological changes were surveyed, and some indexes such as serum fatty, liver index, blood sugar（ GLU）, antioxi- dative ability of liver were examined. Results： Compared to the model group, hepatic index, serum fat , MDA of the high and middle dose Huganqingzhi tablet groups have obviously decreased （ P 〈 0.05 ）, and SOD, CAT, TAOC have obviously increased （ P 〈 0.05 ）. Conelu- siion： The middle （1.08g/kg） and high （2.16g/kg） dose of Huganqingzhi tablet could regulate and prevent the fatty degeneration and in- flammatory injury of the NAFLD rats, reduce the level of blood fatty and develop the ability of oxidation resistance of NAFLD rats.